Skip to content

Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01689051
Enrollment
20
Registered
2012-09-20
Start date
2012-03-31
Completion date
2013-04-30
Last updated
2014-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blod Pressure, Blood Flow, Glucagon-like Peptide-1, Human Physiology, Type 2 Diabetes

Keywords

Type 2 diabetes, Blod pressure, Glucagon-like peptide-1, Human physiology, Blood flow

Brief summary

Diabetes and high blood pressure are risk factors for developing heart disease. An increase in the number of diabetes patients is expected. This increases the number of patients with heart disease, and since the vast majority with diabetes die from heart disease, it is extremely important to investigate how these diseases can be prevented and treated. Studies in animals have shown that intestinal hormone glucagon-like peptide-1 (GLP-1) can expand blood vessels, thus lowering blood pressure, but it is not known whether the effects is found in humans, which we will investigate. Studies have also shown that GLP-1 lowers blood sugar, but it is unclear whether this is solely due to increased insulin production, weight loss associated with GLP-1 intake or GLP-1 has an effect on the muscles which increases the uptake of sugar. We investigate whether GLP-1 enhances the absorption of sugar in the leg. The investigators also examines whether these effects are greater in people with diabetes then in healthy.

Interventions

OTHERhuman glucagon-like peptide 1 (7-36)amide
OTHERhuman glucagon-like peptide 1 (9-36)amide

Sponsors

Danish Heart Foundation
CollaboratorOTHER
University Hospital, Gentofte, Copenhagen
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Written informed consent * T2DM according to WHO's criteria (only T2DM subjects)

Exclusion criteria

* Anemia * T1DM * Severe liver or renal disease * Severe heart disease * Atrial fibrillation

Design outcomes

Primary

MeasureTime frame
Femoral artery blood flow

Secondary

MeasureTime frame
Leg glucose uptake

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026